Vimta Labs

Vimta Labs reported its highest-ever quarterly revenue in Q1 FY26, reaching INR 993 million, a significant 31.4% year-on-year growth compared to INR 756 million in Q1 FY25. EBITDA increased by 33.1% to INR 354 million, with strong margins maintained at 35.7%. Profit After Tax (PAT) also saw robust growth of 35.9%, totaling INR 189 million, and PAT margins stood at 19%. The company emphasized its ability to maintain these strong margins despite external cost pressures.

The company achieved significant regulatory milestones, including a successful US FDA GCP inspection without any Form 483 observations and receipt of cGMP compliance from ANSM EMA. These outcomes underscore Vimta's dedication to quality and scientific precision. In a move to enhance shareholder value and demonstrate confidence in future growth, the Board approved a 1:1 bonus issue.

Vimta Labs is actively expanding into biologics contract research and development services, with equipment procurement currently underway. The commercialization of these services is projected for Q1 FY27. Management highlighted the strategic advantage of offering an end-to-end package to customers, encompassing characterization, analytical, preclinical, clinical research, and formulation development, which differentiates Vimta in the market.

The company has added approximately 200,000 square feet of lab space. Food testing activities have already occupied the new facility, which has, in turn, created additional space in the existing legacy building. This freed-up space is being converted to accommodate contract labs and biologics R&D, allowing for expansion of pharmaceutical services. An additional EMI/EMC chamber has been installed and qualified, with plans to consolidate chambers for optimal equipment use.

For FY26, Vimta Labs has declared a capex outlay of approximately INR 100 crores. About INR 30 crores of this is specifically earmarked for setting up the biologics contract research and development services. The remaining capex will be utilized for expanding capacities across business units, including the purchase of new equipment, replacement of existing equipment, and significant investments in digitizing and automating processes.

Pharmaceutical testing and research services continue to be the primary revenue driver, contributing 65% to 70% of the total business. Food testing activities account for about 20%, while electronics, electrical, and environment testing contribute the remaining 10%. Management noted that the electrical and electronics testing segment is a 'sunrise industry' with growth expected from defense and telecom sectors, driven by indigenous manufacturing and developing regulations.

Despite strong Q1 FY26 margins, management anticipates a potential 1-2% reduction in EBITDA margins over the coming quarters or couple of years. This expected compression is attributed to increased maintenance costs for new capacity, lab redesigning, and rising human resource costs. However, the company aims for a healthy CAGR of 15-20% and is striving to achieve an exit quarterly revenue run rate of INR 120-125 crores for the current fiscal year.

Domestic revenue has remained relatively flat or slightly degrown, which management attributes to the Indian business reaching a mature level with established customer relationships. In contrast, export revenues have grown proportionately to overall business growth, primarily driven by pharmaceutical services. Management views the export market as offering broader opportunities compared to the mature domestic market.